Estrogen receptor ligands: a patent review update

Bibliography

• Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773-81
   PubMed Web of Science ®Google Scholar
• Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-14
   PubMed Web of Science ®Google Scholar
• Jordan VC. Antiestrogens and selective estrogen receptor modulators as multi-functional medicines 1. Receptor interactions. J Med Chem 2003;46:883-908
   PubMed Web of Science ®Google Scholar
• Jordan VC. Antiestrogens and selective estrogen receptor modulators as multi-functional medicines 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-111
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 2012;153:2953-62
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-31
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4
   PubMed Web of Science ®Google Scholar
• Bryant HU. Selective estrogen receptor modulators. Rev Endocr Metab Disord 2002;3:231-41
   PubMedGoogle Scholar
• Minutolo F, Macchia M, Katzenellenbogen JA, et al. Estrogen receptor β ligands: recent advances and biomedical applications. Med Res Rev 2011;31:364-442
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF, Gustafsson J-Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Dis 2011;10:778-92
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011;7:715-26
   PubMed Web of Science ®Google Scholar
• Mohler ML, Narayanan R, Coss CC, et al. Estrogen receptor β selective nonsteroidal estrogens: seeking clinical indications. Expert Opin Ther Pat 2010;20:507-34
   PubMed Web of Science ®Google Scholar
• Ullrich JW, Miller CP. Estrogen receptor modulator review. Expert Opin. Ther Pat 2006;16:559-72
   Google Scholar
• En-cece, Llc. 6-Substituted demethyl-estradiol derivatives as ER-beta agonists. WO2012037261; 2012
   Google Scholar
• Schering Ag. 9α-Substituted estratrienes as selectively active estrogens. WO2003104253; 2003
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. 9-Alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer. WO2010003700; 2010
   Google Scholar
• Schering Ag. Prevention and treatment of hypertensive heart diseases by the selective estrogens 8β-vinyl-estra-1,3,5(10)-trien-3,17β-diol and 17β-fluor-9α-vinyl-estra-1,3,5(10)-trien-3,16α-diol. WO2005051401; 2005
   Google Scholar
• Merck & CO. Estrogen receptor modulators. WO2006012333; 2006
   Google Scholar
• Merck & CO. Estrogen receptor modulators. WO2006009912; 2006
   Google Scholar
• Jenapharma Gmbh. 19-Nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring. US20020156274; 2001
   Google Scholar
• Schering Ag. 19-Nor-17-α-pregna-1,3,5(10)-trien-17β-ols containing 21,16α-lactone ring substituted with a long chain at the 11β position. WO03080641; 2003
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic A-ring. WO2010009828; 2010
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. 14,17-Bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic A-ring. WO2011092127; 2011
   Google Scholar
• Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73
   PubMed Web of Science ®Google Scholar
• Imperial Chemical Industries. Therapeutic product for the treatment of peri- or postmenopausal conditions. EP0346014; 1989
   Google Scholar
• Morgan Lewis & Bockius LLP. Use of Fulvestrant in the treatment of resistant breast cancer. US2011183949; 2011
   Google Scholar
• Astrazeneca. Fulvestrant in a dosage of 500 mg for the treatment of advanced breast cancer. WO2011012885; 2011
   Google Scholar
• University of Southern California. Estrogen receptor modulators, associated pharmaceutical compositions and methods of use. WO2008100560; 2008
   Google Scholar
• Jia W. Prevention of breast cancer with novel selective estrogen receptor modulators. CA2481664; 2006
   Google Scholar
• Topass GmbH. Estrogen receptors α and β ligands, method for their preparation and pharmaceutical agents comprising thereof. CZ300376; 2009
   Google Scholar
• Topass Gmbh. Preparation of 6-oxa-8a-steroid estrogen analogs - a new group of unnatural estrogens and their use in medicine. WO2009059806; 2009
   Google Scholar
• N.V. Organon. 16,17-Carbocyclic condensed steroid compounds having selective estrogenic activity. US7868193; 2011
   Google Scholar
• Wyeth. Substituted benzoxazole as estrogenic agents. US20030199562; 2003
   Google Scholar
• Wyeth. Use of ER-beta selective ligands for treating acute lung injuries. US20080182872; 2008
   Google Scholar
• Study Evaluating ERB-041 in Active Crohn's Disease. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2005. Available from: www.clinicaltrials.gov/ct2/show/NCT00245947 [Last Accessed 3 December 2012]
   Google Scholar
• Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2005. Available from: www.clinicaltrials.gov/ct2/show/NCT00110487 [Last Accessed 3 December 2012]
   Google Scholar
• Wyeth. Phosphate derivatives of substituted benzoxazoles. WO2009100335; 2009
   Google Scholar
• Wyeth. Prodrug substituted benzoxazoles as estrogenic agents. US20060046968; 2006
   Google Scholar
• N.V. Organon. Isoxazole derivatives used as estrogen receptor modulators. WO2012052395; 2012
   Google Scholar
• Pulkkinen. Novel 4,5-dihydroisoxazoles with estrogenic activity. WO2009066009; 2009
   Google Scholar
• Poutiainen PK, Venäläinen TA, Peräkylä M. Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazolesand 3-hydroxy ketones as estrogen receptor α and β agonists. Bioorg Med Chem 2010;18:3437-47
   PubMed Web of Science ®Google Scholar
• Pfizer Products, Inc. Estrogen modulators. WO2007072164; 2007
   Google Scholar
• Organon Usa, Inc. Tetrahydronaphthalen-2-ol derivatives. US20100240748; 2010
   Google Scholar
• Eli Lilly and Co. Substituted tetralins as selective estrogen receptor-beta agonists. WO2006088716; 2006
   Google Scholar
• Eli Lilly and Co. Selective estrogen receptor modulators. WO2010036497; 2010
   Google Scholar
• Dal-Housie University. Selective estrogen receptor modulators. WO2012079154; 2012
   Google Scholar
• Eisai. Selective estrogen receptor modulators. US20060116364; 2006
   Google Scholar
• SmithKline Beecham Corp. Chemical compounds. WO2006002185; 2006
   Google Scholar
• Pfizer Products, Inc. Lasofoxifene tablets and its coating. WO2004006895; 2004
   Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
   PubMed Web of Science ®Google Scholar
• Pfizer Products, Inc. Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist. WO2004064832; 2004
   Google Scholar
• Brinton. Phytoestrogenic formulations and use thereof. WO2008016768; 2009
   Google Scholar
• Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists. US20090042818; 2009
   Google Scholar
• Bionovo, Inc. Estrogenic compounds and their method of use. US20100234310; 2010
   Google Scholar
• Li J, Meng K. Compounds and methods for treating estrogen receptor related diseases. US20100016352; 2010
   Google Scholar
• Universiatit Gent. Naringenin derivatives with selectivity on ERs. WO2007053915; 2007
   Google Scholar
• Eli Lilly and Co. Substituted benzopyrans as selective estrogen receptor-beta agonists. WO03074044; 2003
   Google Scholar
• Eli Lilly and Co. Substituted benzopyrans as selective estrogen receptor-beta agonists. WO03044006; 2003
   Google Scholar
• Eli Lilly and Co. Substituted benzopyrans as selective estrogen receptor-beta agonists. WO2006044176; 2006
   Google Scholar
• Trinity College Dublin. Selective estrogen receptor modulators. IE20070466; 2007
   Google Scholar
• Janssen Pharmaceutica N.V. Novel 2H-chromene derivatives as selective estrogen receptor modulators. WO2006055694; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of estrogen receptors. WO2006078834; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. Novel spiro-benzo[c]chromene derivatives useful as modulators of estrogen receptors. US20060020018; 2006
   Google Scholar
• Argon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof. WO2011156518; 2011
   Google Scholar
• Trembley A, Tremblay GB, Labrie C, et al. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology 1998;139:111-18
   PubMed Web of Science ®Google Scholar
• Endorecherche, Inc. Benzopyran-containing compounds and method for their use. US6060503; 2000
   Google Scholar
• Acolbifene for Breast Cancer Chemoprevention. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00853996 [Last Accessed 3 January 2013]
   Google Scholar
• Karo Bio AB. Substituted thiophenes or furans as estrogen receptor ligands. WO2012022776; 2012
   Google Scholar
• Msd Oss B.V. N-Substituted azetidine derivatives. WO2012084711; 2012
   Google Scholar
• Karo Bio AB. Therapeutic 2-(4-substituted-phenyl)-3-(cyclyl containing)-5-hydroxy-benzo[b]thiophene derivatives as estrogen receptor ligands. GB2459133; 2009
   Google Scholar
• Eli Lilly and Co. Antiestrogenic and antidrugenic benzothiophenes. US4418068; 1983
   Google Scholar
• Eli Lilly and Co. Prevention of breast cancer with selective estrogen receptor modulators. WO9845286; 1998
   Google Scholar
• Eli Lilly and Co. Treatment of central nervous system disorders with selective estrogen receptor modulators. WO9845287; 1998
   Google Scholar
• Eli Lilly and Co. Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators. WO9845288; 1998
   Google Scholar
• Thatcher GRJ, Bolton J, Petukhov PA, et al. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem 2007;50:2682-92
   PubMed Web of Science ®Google Scholar
• Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86
   PubMed Web of Science ®Google Scholar
• Farmos Group Ltd. Novel tri-phenyl alkane and alkene derivatives and their preparation and use. US4696949; 1986
   Google Scholar
• Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia). ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2005. Available from: www.clinicaltrials.gov/ct2/show/NCT00106691 [Last Accessed 11 January 2013]
   Google Scholar
• SmithKline Beecham Corp. Chemical compounds. WO2007062151; 2007
   Google Scholar
• Schering Ag. Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate. US4310523; 1982
   Google Scholar
• Applied Research Systems ARS Holding N.V. Use of clomiphene for the treatment of infertility. EP0430388; 1989
   Google Scholar
• Argon Pharmaceuticals Inc. Estrogen receptor modulators and uses thereof. WO2012037411; 2012
   Google Scholar
• SmithKline Beecham Corp. Chemical compounds. WO2007062148; 2007
   Google Scholar
• Univ Holy Ghost Duquesne. Anti-cancer tamoxifen-melatonin hybrid ligand. WO2011046596; 2011
   Google Scholar
• Novacea, Inc. Treatment of hyperproliferative disease with N-oxides of estrogen receptor modulators. WO2007098090; 2009
   Google Scholar
• Karo Bio AB. Substituted pyrazoles as estrogen receptor ligands. WO2011042475; 2011
   Google Scholar
• Laboratoire Theramex. Indazoles, benzisoxazoles, and benzisothiazoles as estrogenic agents. EP1647549; 2006
   Google Scholar
• Board of Trustees of University of Illinois. Estrogen receptor ligands. WO2000019994; 2000
   Google Scholar
• Karo Bio AB. Substituted pyrroles and imidazoles as estrogen receptor ligands. WO2011042477; 2011
   Google Scholar
• Karo Bio AB. Novel estrogen receptor ligands. WO2010031852; 2010
   Google Scholar
• Karo Bio AB. Novel estrogen receptor ligands. WO2011042473; 2011
   Google Scholar
• Karo Bio AB. Fused pyrrole derivatives as estrogen receptor ligands. WO2012136772; 2012
   Google Scholar
• Wyeth. Bazedoxifene treatment regimens. WO03105834; 2003
   Google Scholar
• Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00853996 [Last Accessed 16 March 2013]
   Google Scholar
• Katzenellenbogen JA, Katzenellenbogen BS, Compton DR. Sulfonamides as selective estrogen receptor. US20070021495; 2007
   Google Scholar
• University of medicine and dentistry of New Jersey. Estrogen receptor modulators and uses thereof. WO2008006093; 2008
   Google Scholar
• Bristol Myers Squibb Co. Alkylene-bridged sultam compounds useful as modulators of nuclear hormone receptor function. WO2008030902; 2008
   Google Scholar
• Dalton JT. Estrogen receptor ligands and uses thereof. US20120077485; 2012
   Google Scholar
• Wyeth. Condensed compounds with activity at estrogen receptors. WO2009055734; 2009
   Google Scholar
• Acadia Pharmaceuticals, Inc. Novel estrogen receptor ligands. WO2009124968; 2009
   Google Scholar
• Biotropics Malaysia Berhad. Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases. WO2010110647; 2010
   Google Scholar
• Katzenellenbogen JA, Katzenellenbogen BS, Carlson KE, et al. Estrogen receptor β potency-selective ligands: Structure-activity relationship studies of diarylproprionitriles and their acetylene and polar analogues. J Med Chem 2001;44:4230-51
   PubMed Web of Science ®Google Scholar
• Radius Health, Inc. Estrogen receptor ligands. WO2010030787; 2010
   Google Scholar
• Acadia Pharmaceutical, Inc. Compounds with activity at estrogen receptors. WO2008033894; 2008
   Google Scholar
• Acadia Pharmaceutical, Inc. Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptor beta. WO2013017619; 2013
   Google Scholar
• Karo Bio AB. Novel estrogen receptor ligands. WO2013017654; 2013
   Google Scholar
• Northeastern University. Modulators of nuclear receptor co-regulatory protein binding. WO2009117739; 2009
   Google Scholar
• SmithKline Beecham Corp. Cyclic alkylidene-phenol compounds as selective estrogen receptor modulators. WO2008030771; 2008
   Google Scholar
• Rohrer SP, Shaeffer JM, Hayes EC, et al. The discovery of tetrahydrofluorenones as a new class of estrogen receptor β-subtype selective ligands. Bioorg Med Chem Lett 2006;16:3489-94
   PubMed Web of Science ®Google Scholar
• Rohrer SP, Shaeffer JM, Hayes EC, et al. Estrogen receptor β-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere. Bioorg Med Chem Lett 2006;16:3896-901
   PubMed Web of Science ®Google Scholar
• Rohrer SP, Hammond LM, Birzin ET, et al. Tetrahydrofluorenones with conformationally restricted side chain as estrogen receptor beta ligands. Bioorg Med Chem Lett 2006;16:4462-6
   PubMed Web of Science ®Google Scholar
• Merck & Co. Selective estrogen receptor modulators. WO2003015761; 2006
   Google Scholar
• Merck & Co. Estrogen receptor modulators. WO2006062876; 2006
   Google Scholar
• Merck & Co. Estrogen receptor modulators. WO2008057309; 2008
   Google Scholar
• Minutolo F, Bertni S, Papi C, et al. Salicylaldoxime Moiety as a Phenolic “A-Ring” Substitute in Estrogen Receptor Ligands. J Med Chem 2001;44:4288-91
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, Bellini R, et al. Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem 2008;51:1344-51
   PubMed Web of Science ®Google Scholar
• Wyeth. Hydroxybiphenylcarbaldehyde oxime derivatives and their use as estrogenic agents. WO2004099122; 2004
   Google Scholar
• Mewshaw RE, Manas ES, Harris HA, et al. ERβ ligands. Part 2: Synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg Med Chem Lett 2004;12:2553-70
   Google Scholar
• Wyeth. Aryl carbaldehyde oxime derivatives and their use as estrogenic agents. WO2004103941; 2004
   Google Scholar
• Wyeth. (4-Hydroxyphenyl)-1H-indole-3-carbaldehyde oximes derivatives as estrogenic agents. WO2005018636; 2005
   Google Scholar
• Mewshaw RE, Manas ES, Harris HA, et al. ERβ ligands. Part 5: Synthesis and structure–activity relationships of a series of 40-hydroxyphenyl-aryl carbaldehyde oxime derivatives. Bioorg Med Chem Lett 2007;17:902-6
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb Co. C5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators. WO2006116401; 2006
   Google Scholar
• Feyen JHM, Seethala R, Jonhson SE, et al. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem 2006;49:2440-55
   PubMed Web of Science ®Google Scholar
• Virginia Commonwealth University. Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases. US20060287359; 2006
   Google Scholar
• Novartis AG. Phenylisoquinoline and phenylquinazoline derivatives for the treatment of bone diseases. WO2009027475; 2009
   Google Scholar
• Wyeth. Estrogen receptor ligands. US20060019961; 2006
   Google Scholar
• Wyeth. [Pyrrolo[1,2-a]quinoxalin-5(4H)-yl]sulfonyls and carbonyls and their use as estrogenic agents. WO2006068928; 2006
   Google Scholar
• Johnson & Johnson. Benzoxazepine derivatives as selective estrogen receptor modulators. US20060040917; 2006
   Google Scholar
• Aragon Pharmaceuticals. Indane estrogen receptor modulators and use thereof. WO2011159769; 2011
   Google Scholar
• Karo Bio AB. 2-Phenyl indene derivatives useful as estrogen receptor ligands. WO2008043567; 2008
   Google Scholar
• Karo Bio AB. Indene derivatives as estrogen receptor ligands. WO2009121910; 2009
   Google Scholar
• Karo Bio AB. Novel estrogen receptor ligands. WO2009012954; 2009
   Google Scholar
• Wyeth. 6H-[1]Benzopyrano-[4,3-B]quinolines and their use as estrogenic agents. US20060052410; 2006
   Google Scholar
• Wyeth. Tetracyclic compounds as estrogenic ligands. US20060004087; 2006
   Google Scholar
• Karo Bio AB. Novel estrogen receptor ligands. WO2011042474; 2011
   Google Scholar
• Pulkkinen J, Honkakoski P, Peräkylä M, et al. Novel β-hydroxyketones and β-alkoxyketones with estrogenic activity. WO2009066008; 2009
   Google Scholar
• The Board of Trustees of the University of Illinois. Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer. US20090291972; 2009
   Google Scholar
• Florida A&M University. SERMS for the treatment of estrogen receptor-mediated disorders. WO2012142029; 2012
   Google Scholar
• Bionovo, Inc. Nyasol and analogs thereof for the treatment of estrogen receptor beta -mediated diseases. US20090312274; 2009
   Google Scholar
• Filardo J, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Tends Endocrinol Metab 2005;16:362-7
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Sklar LA, Oprea TI, et al. GPR30: a novel therapeutic target in estrogen related disease. Trends Pharmacol Sci 2008;29:116-23
   PubMed Web of Science ®Google Scholar
• Science and Tecnology Corp @ UNM. Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof. WO2007019180; 2007
   Google Scholar
• Fox Chase Cancer Center. Methods for inhibiting proliferation and inducing apoptosis of cancer cells expressing the G protein-coupled estrogen receptor GPR30. WO2012122101; 2012
   Google Scholar
• Oncotherapy Science, Inc., Univ Tokyo. Method for diagnosing and treating renal cells carcinoma. WO2007013575; 2007
   Google Scholar
• Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997;62:268-303
   PubMed Web of Science ®Google Scholar
• Pike ACW, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-18
   PubMed Web of Science ®Google Scholar
• Pike ACW, Brzozowski AM, Walton J, et al. Structural Insights into the Mode of Action of a Pure Antiestrogen. Structure 2001;9:145-53
   PubMed Web of Science ®Google Scholar
• Schering Aktiengesellschaft. Use of ERSS-selective ligands for regulating fertility and compounds useful therefore. WO02068548; 2002
   Google Scholar
• Available from: https://scifinder.cas.org/ [Last accessed 28 February 2013]
   Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;124:199-205
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS. a randomised trial Lancet 2013;381(9869):805-16
   Google Scholar
• Coss CC, Jones A, Parke DN, et al. Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer. Endocrinology 2012;153:1070-81
   PubMed Web of Science ®Google Scholar
• Yalamanchili V, Gallagher JC. Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause 2012;19:697-703
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Houbiers JGA, Buttgereit F, et al. The selective estrogen receptor α agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity. Arthritis Rheum 2010;62:351-8
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Castañeda S, Cutolo M, et al. Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res 2010;62:1588-93
   PubMed Web of Science ®Google Scholar
• Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16:458-65
   PubMed Web of Science ®Google Scholar
• Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence (CRC). ClinicalTrial.gov. A service of the U.S. National Institutes of Health. 2011. Available from: www.clinicaltrials.gov/ct2/show/NCT01402648 [Last Accessed 28 December 2012]
   Google Scholar
• Thorp AA, Sinn N, Buckley JD, et al. Soya isoflavone supplementation enhances spatial working memory in men. Br J Nutr 2009;102:1348-54
   PubMed Web of Science ®Google Scholar
• Jackson RL, Greiwe JS, Desai PB, et al. Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor β-agonist being developed for the treatment of menopausal symptoms. Menopause 2011;18:185-93
   PubMed Web of Science ®Google Scholar
• Dalton JT. Nuclear receptor binding agents. US2012157539; 2012
   Google Scholar
• Minutolo F, Bertini S, Macchia M, et al. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-substituted 3,4-diarylsalicylaldoximes on estrogen receptors α and β. Bioorg Med Chem 2003;11:1247-57
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, Macchia M, et al. Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem 2003;46:4032-42
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, Macchia M, et al. Synthesis of anthranylaldoxime derivatives as estrogen receptor ligands and computational prediction of binding modes. J Med Chem 2006;49:5001-12
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, Granchi C, et al. Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta. J Med Chem 2009;52:858-67
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, De Cupertinis A, et al. Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes. Eur J Med Chem 2011;46:2453-62
   PubMed Web of Science ®Google Scholar